SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as community excitement builds over impending EU approval for its Anktiva therapy and Saudi Arabia's expanding commitment to "all cancers" with IBRX, with many anticipating a significant short squeeze. Investors see the company as deeply undervalued, driven by its innovative immunotherapy's potential for widespread adoption in immune restoration and cancer treatment.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is seeing significant discussion and extreme volatility after Novo Nordisk filed a patent infringement lawsuit over its compounded semaglutide products, which Hims has since ceased, with the community sharply divided between concerns over legal and regulatory risks and the belief that the stock is oversold with short-squeeze potential.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl is trending after a sharp stock drop driven by a deteriorated financial outlook, unexpected leadership changes, a delayed filing, and an SEC probe into its accounting practices, leading to a community split between those seeing an oversold buying opportunity and others fearing significant financial irregularities.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

monday.com is experiencing a sharp decline after issuing weaker-than-expected guidance and withdrawing long-term targets, intensifying market fears that AI could disrupt its traditional software business model. The community is sharply divided, with some viewing the brutal sell-off as an overreaction given the company's strong cash position and enterprise growth, while others believe AI tools pose a significant threat to the SaaS sector.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean ($RIG) is trending as the community reacts to its recent all-stock acquisition of Valaris ($VAL) for $5.8 billion, a deal many see as creating a premier offshore drilling leader poised to capitalize on an emerging multi-year upcycle, though some investors are debating the implications of the merger for share dilution and the combined company's future.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending following an 'Overweight' initiation and bullish price target from Morgan Stanley, amplifying the narrative around its strategic pivot to AI and high-performance computing data centers. The community is actively discussing the company's strong power infrastructure and key partnerships, like Google, positioning it favorably amidst booming demand for computing capacity, despite some noting its historical correlation with Bitcoin prices.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending amid a significant stock plunge despite a reported earnings beat and new share buyback, fueled by concerns over Meta's Instagram developing a rival app. The community is sharply divided, with many blaming CEO Evan Spiegel's leadership while others see an extreme oversold opportunity given its user growth and AR smartglasses ambitions.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending down sharply after its mixed Q4 earnings report, featuring a revenue miss and conservative forward guidance. This has ignited intense community debate over whether the fintech stock is now severely undervalued and a buying opportunity, or if the market is overreacting amidst broader sector weakness.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

AMKR is gaining significant attention for its central role in advanced semiconductor packaging, which is vital for the booming AI sector and enhanced by strategic collaborations with industry leaders like Apple, Nvidia, and TSMC. The community views the company as a key beneficiary of the U.S. manufacturing reshoring trend, anticipating substantial long-term growth as it expands its domestic capabilities.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is a major talking point after reporting losses, though management projected a brighter 2026 with an expiring unfavorable slab contract and active strategic partnership discussions with POSCO. The community is sharply divided, with critics citing past underperformance and a significant post-earnings stock drop, while bulls see the stock as deeply undervalued with strong potential catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fractyl Health, Inc. (NASDAQ:GUTS) Receives Consensus Recommendation of "Hold" from Analysts

Shares of Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) have received a consensus rating of "Hold" from the five brokerages that are currently covering the firm, Marketbeat.com reports. One...

Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights GUTS

The DJS Law Group announces that it is investigating claims on behalf of investors of Fractyl Health, Inc. (Fractyl Health or the Company) (NASDAQ: GUTS) for violations of the securities laws...

Fractyl Health Showcases 6-Month REMAIN-1 Data as Revita Curbs Post-GLP-1 Weight Regain

Fractyl Health (NASDAQ:GUTS) presented prospective, randomized, double-blind, controlled six-month data from its REMAIN-1 midpoint cohort pilot study, highlighting results the company said support...

<ul class="summary-bullets"><li>The results reinforce the device’s potential durability and support continued study in the pivotal REMAIN-1 trial.&nbsp;</li><li>Beyond weight maintenance, Revita-treated participants demonstrated improvements in lipid profiles.</li><li>Patient-reported outcomes also indicated reduced cravings for sweet foods.</li></ul>Fractyl Health, Inc. (GUTS) announced on Thursday positive six-month findings from its ongoing REMAIN-1 Midpoint Cohort, a study evaluating Revita for weight maintenance after patients discontinue GLP-1 therapy.The six-month data, covering 40 participants, suggest that Revita helps limit weight regain following GLP-1 discontinuation, with treated patients regaining 4.5% of weight versus 7.5% in the sham group.<h2 class="st-heading-2">Midpoint Study Shows Promising Results</h2>An exploratory analysis of those who lost above-median weight during the GLP-1 run-in showed a 70% relative reduction in post-GLP-1 weight regain for Revita-treated participants compared with sham.&nbsp;These results reinforce the device’s potential durability and support continued study in the pivotal REMAIN-1 trial. Beyond weight maintenance, Revita-treated participants demonstrated improvements in lipid profiles, including higher HDL cholesterol and a lower triglyceride-to-HDL ratio.&nbsp;Patient-reported outcomes also indicated reduced cravings for sweet foods, suggesting that the device may influence appetite and metabolism through gut-mediated mechanisms.However,&nbsp;<a href="https://stocktwits.com/symbol/GUTS">Fractyl Health's stock</a> plummeted 63% in Thursday’s premarket.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React</h2>Despite the fall in the stock’s price, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_29_085922_png_07f795b807.webp" alt="GUTS’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 29, 2026 | Source: Stocktwits" width="930" height="110"><figcaption>GUTS’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 29, 2026 | Source: Stocktwits</figcaption></figure>A bullish Stocktwits user said the product that reduces sweet cravings could be extremely profitable, highlighting huge market potential.<stembedurl>https://stocktwits.com/BioRich/message/643264512</stembedurl>Another user said they trusted the management and would hold the stock.&nbsp;<stembedurl>https://stocktwits.com/CocoPeechu/message/643264755</stembedurl>Revita, the main product from Fractyl Health, is meant to reshape the lining of the small intestine through a single, minimally invasive procedure. The FDA has granted Revita Breakthrough Device designation to help people maintain weight after stopping GLP-1 treatments.The company also outlined upcoming catalysts, including one‑year cohort readouts and pivotal REMAIN‑1 data later this year, which could support a future U.S. marketing application.GUTS stock has declined by over 9% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-now-stock-is-falling/cmyifBjR4KZ">NOW Stock Falls 9% After Q4 Beat: Why Have Analysts Cut Price Targets?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

Why Did GUTS Stock Plummet Today Despite Positive Gut Therapy Midterm Study? 

Six-month data from 40 participants suggest that Revita helps limit weight regain after GLP-1 discontinuation.

Equity

Six-month data from 40 participants suggest that Revita helps limit weight regain after GLP-1 discontinuation.


HC Wainwright Forecasts Fractyl Health FY2030 Earnings

Fractyl Health, Inc. (NASDAQ:GUTS - Free Report) - Equities researchers at HC Wainwright issued their FY2030 EPS estimates for Fractyl Health in a research report issued to clients and investors on...

Short Interest in Fractyl Health, Inc. (NASDAQ:GUTS) Expands By 24.0%

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 11,893,654 shares, a growth...

Fractyl Health, Inc. (NASDAQ:GUTS) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five research firms that are covering the firm, MarketBeat reports. One...

Fractyl Health, Inc. (NASDAQ:GUTS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the five ratings firms that are currently covering the firm, MarketBeat reports...

Fractyl Health (NASDAQ:GUTS) CEO Acquires $19,998.72 in Stock

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) CEO Harith Rajagopalan bought 10,416 shares of the stock in a transaction on Thursday, December 4th. The stock was acquired at an average cost of...

Insider Buying: Fractyl Health (NASDAQ:GUTS) CEO Buys 10,416 Shares of Stock

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) CEO Harith Rajagopalan bought 10,416 shares of the firm's stock in a transaction that occurred on Thursday, December 4th. The shares were acquired...

Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.

Fractyl Health Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$0.4381
Prev Close	$0.415
Open	$0.4132
Dividend Yield	0.00%
50-Day Moving Average	$1.84
Beta	1.25
Avg. Volume	9.79M
PE Ratio	-0.18

52-Week High	$3.03
52-Week Low	$0.3772
Market Capitalization	$56.87M
EPS (Annual)	-$1.44
Price to Book	-17.26
Revenue Per Employee	$869.16
Enterprise Value/EBITDA	N/A

GUTS
Fractyl Health Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GUTS News

GUTSFractyl Health Inc.